

Soo Aleman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7401504/publications.pdf>

Version: 2024-02-01

78
papers

8,108
citations

218677
26
h-index

74163
75
g-index

83
all docs

83
docs citations

83
times ranked

14215
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	8.1	1,619
2	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. <i>Cell</i> , 2020, 183, 158-168.e14.	28.9	1,561
3	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	8.1	1,241
4	Natural killer cell immunotypes related to COVID-19 disease severity. <i>Science Immunology</i> , 2020, 5, .	11.9	344
5	Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. <i>Nature Medicine</i> , 2022, 28, 472-476.	30.7	333
6	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	8.1	237
7	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2017, 66, 485-493.	3.7	225
8	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	8.1	208
9	Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. <i>New England Journal of Medicine</i> , 2020, 382, 1018-1028.	27.0	208
10	A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis. <i>Clinical Infectious Diseases</i> , 2013, 57, 230-236.	5.8	206
11	Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. <i>EBioMedicine</i> , 2021, 74, 103705.	6.1	161
12	MAIT cell activation and dynamics associated with COVID-19 disease severity. <i>Science Immunology</i> , 2020, 5, .	11.9	147
13	Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	104
14	Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. <i>Aids</i> , 2002, 16, 1039-1044.	2.2	99
15	Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. <i>Annals of Internal Medicine</i> , 2019, 171, 318.	3.9	95
16	Tissue-resident MAIT cell populations in human oral mucosa exhibit an activated profile and produce IL-17. <i>European Journal of Immunology</i> , 2019, 49, 133-143.	2.9	85
17	Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. <i>Journal of Viral Hepatitis</i> , 2008, 15, 538-550.	2.0	67
18	Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. <i>Hepatology</i> , 2020, 72, 1177-1190.	7.3	65

#	ARTICLE	IF	CITATIONS
19	Innate lymphoid cell composition associates with COVID-19 disease severity. <i>Clinical and Translational Immunology</i> , 2020, 9, e1224.	3.8	56
20	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. <i>Clinical Infectious Diseases</i> , 2019, 69, 2218-2227.	5.8	52
21	High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	52
22	Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys. <i>Journal of Infectious Diseases</i> , 2021, 224, 407-414.	4.0	43
23	Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C. <i>Clinical Infectious Diseases</i> , 2016, 63, 723-729.	5.8	41
24	SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation. <i>Clinical and Translational Immunology</i> , 2021, 10, e1306.	3.8	36
25	The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 233-244.	1.5	33
26	Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus. <i>Liver International</i> , 2020, 40, 1832-1840.	3.9	31
27	Expansion of donor-unrestricted MAIT cells with enhanced cytolytic function suitable for TCR redirection. <i>JCI Insight</i> , 2021, 6, .	5.0	29
28	Hepatitis C infection among injection drug users in Stockholm Sweden: Prevalence and gender. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 679-684.	1.5	28
29	TCR-Redirected Human T Cells Inhibit Hepatitis C Virus Replication: Hepatotoxic Potential Is Linked to Antigen Specificity and Functional Avidity. <i>Journal of Immunology</i> , 2012, 189, 4510-4519.	0.8	24
30	High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV – but HIV viremia matters?. <i>Aids</i> , 2022, 36, 479-481.	2.2	24
31	Management of hepatitis B virus infection, updated Swedish guidelines. <i>Infectious Diseases</i> , 2020, 52, 1-22.	2.8	23
32	Treatment of hepatitis C virus infection for adults and children: updated Swedish consensus guidelines 2017. <i>Infectious Diseases</i> , 2018, 50, 569-583.	2.8	20
33	Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1431-1442.	2.0	20
34	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. <i>Med</i> , 2022, 3, 137-153.e3.	4.4	19
35	High Plasma Levels of Soluble Fas in HIV Type 1-Infected Subjects Are Not Normalized during Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1379-1384.	1.1	18
36	Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1378-1386.	1.5	18

#	ARTICLE	IF	CITATIONS
37	NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals. <i>Molecular Medicine</i> , 2022, 28, 20.	4.4	18
38	MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccine. <i>Molecular Medicine</i> , 2022, 28, 54.	4.4	18
39	Long-Term Effects of Antiretroviral Combination Therapy on HIV Type 1 DNA Levels. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1249-1254.	1.1	17
40	Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 506-513.	1.6	16
41	Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County. <i>BMC Infectious Diseases</i> , 2019, 19, 955.	2.9	15
42	Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016. <i>Infectious Diseases</i> , 2017, 49, 561-575.	2.8	14
43	T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial. <i>Haematologica</i> , 2022, 107, 1000-1003.	3.5	14
44	Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron. <i>Nature Medicine</i> , 0, , .	30.7	14
45	Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon- β production. <i>Gut</i> , 2012, 61, 589-596.	12.1	13
46	Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 502-521.	1.5	13
47	Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties. <i>Journal of Virology</i> , 2017, 91, .	3.4	13
48	IL13R α 2 expression identifies tissue-resident IL-22-producing PLZF ⁺ innate T cells in the human liver. <i>European Journal of Immunology</i> , 2018, 48, 1329-1335.	2.9	13
49	Elevated CD21 ^{low} B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2022, 42, 716-727.	3.8	13
50	Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant. <i>Journal of Clinical Immunology</i> , 2022, 42, 1130-1136.	3.8	13
51	Health check-ups and family screening allow detection of hereditary hemochromatosis with less advanced liver fibrosis and survival comparable with the general population. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 1118-1126.	1.5	12
52	Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. <i>Infectious Diseases</i> , 2016, 48, 251-261.	2.8	12
53	Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 61-68.	1.5	12
54	Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 178-183.	1.5	12

#	ARTICLE	IF	CITATIONS
55	Chronic hepatitis B virus infection and the risk of hepatocellular carcinoma by age and country of origin in people living in Sweden: A national register study. <i>Hepatology Communications</i> , 2022, 6, 2418-2430.	4.3	12
56	Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101564.	1.5	11
57	Hepatocellular carcinoma in individuals with HBV infection or HBV/HCV co-infection in a low endemic country. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 944-952.	1.5	10
58	Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1042-1050.	1.5	10
59	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	4.9	10
60	Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection. <i>Scientific Reports</i> , 2020, 10, 2081.	3.3	9
61	Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19. <i>Liver International</i> , 2021, 41, 2024-2031.	3.9	9
62	Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study. <i>PLoS ONE</i> , 2018, 13, e0190146.	2.5	9
63	Hepatitis C Virus Infection and the Temporal Trends in the Risk of Liver Cancer: A National Register-Based Cohort Study in Sweden. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 63-70.	2.5	7
64	COVID-19-specific metabolic imprint yields insights into multiorgan system perturbations. <i>European Journal of Immunology</i> , 2022, 52, 503-510.	2.9	7
65	Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies. <i>Cells</i> , 2020, 9, 1471.	4.1	6
66	Kinetics of β -Chemokine Levels during Anti-HIV Therapy. <i>Antiviral Therapy</i> , 1999, 4, 109-115.	1.0	6
67	Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients. <i>Biochemical and Biophysical Research Communications</i> , 2013, 433, 31-35.	2.1	5
68	Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions. <i>JHEP Reports</i> , 2021, 3, 100318.	4.9	5
69	Functional Attributes of Responding T Cells in HCV Infection: The Recent Advances in Engineering Functional Antiviral T Cells. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2014, 62, 23-30.	2.3	4
70	Probabilistic classification of anti-SARS-CoV-2 antibody responses improves seroprevalence estimates. <i>Clinical and Translational Immunology</i> , 2022, 11, e1379.	3.8	4
71	The Karolinska COVID-19 immune atlas: An open resource for immunological research and educational purposes. <i>Scandinavian Journal of Immunology</i> , 2022, 96, .	2.7	4
72	Evidence for B cell maturation but not trained immunity in uninfected infants exposed to hepatitis C virus. <i>Gut</i> , 2020, 69, 2203-2213.	12.1	3

#	ARTICLE	IF	CITATIONS
73	Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with direct-acting antivirals. <i>GastroHep</i> , 2021, 3, 185-195.	0.6	3
74	Mortality among amphetamine users with hepatitis C virus infection: A nationwide study. <i>PLoS ONE</i> , 2021, 16, e0253710.	2.5	3
75	Minor nef gene alterations after human HIV-DNA immunisation. <i>Aids</i> , 2004, 18, 817-819.	2.2	2
76	High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 574-580.	1.5	1
77	The hurdle with remaining risk for hepatocellular carcinoma in cirrhotic patients after a hepatitis C cure. <i>Hepatology, Medicine and Policy</i> , 2016, 1, 11.	1.7	0
78	REPLY:. <i>Hepatology</i> , 2021, 74, 1127-1128.	7.3	0